Jan 21, 2021Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates
Jan 19, 2021Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
Nov 09, 2020Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020
Aug 13, 2020Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series
Jun 27, 2020Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting
Jun 17, 2020Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
